A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

BACKGROUND: The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has shown clinical activity as monotherapy in phase I and II studies of advanced ca...

Descripción completa

Detalles Bibliográficos
Autores principales: LoRusso, Patricia M., Infante, Jeffrey R., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., Cohen, Roger B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340007/
https://www.ncbi.nlm.nih.gov/pubmed/28264648
http://dx.doi.org/10.1186/s12885-017-3143-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340007/
https://www.ncbi.nlm.nih.gov/pubmed/28264648
http://dx.doi.org/10.1186/s12885-017-3143-6

Ejemplares similares